Read by QxMD icon Read


Brady Lonergan, Eliza Nguyen, Cara Lembo, Carrie Hinchman, Oscar G Morales, Daniel Z Press, Alvaro Pascual-Leone, Adam P Stern
Four transcranial magnetic stimulation (TMS) devices are currently approved for use in treatment-resistant depression. The authors present the first data-driven study examining the patient- and technician-experience using three of these distinct devices. A retrospective survey design with both patient and technician arms was utilized. The study population included patients who received TMS for treatment-resistant depression at the Berenson Allen Center for Noninvasive Brain Stimulation for the first time between 2013 and 2016 and technicians who worked in the program from 2009 to 2017...
January 25, 2018: Journal of Neuropsychiatry and Clinical Neurosciences
Wolfgang Bothe, Harald Schubert, Mahmoud Diab, Gloria Faerber, Christoph Bettag, Xiaoyan Jiang, Martin S Fischer, Joachim Denzler, Torsten Doenst
PURPOSE: Recently, algorithms were developed to track radiopaque markers in the heart fully automated. However, the methodology did not allow to assign the exact anatomical location to each marker. In this case study we describe the steps from the generation of three-dimensional marker coordinates to quantitative data analyses in an in vivo ovine model. METHODS: In one adult sheep, twenty silver balls were sutured to the right side of the heart: 10 to the tricuspid annulus, one to the anterior tricuspid leaflet and nine to the epicardial surface of the right ventricle...
2016: SpringerPlus
Jared C Horvath, John Mathews, Mark A Demitrack, Alvaro Pascual-Leone
The Neuronetics NeuroStar Transcranial Magnetic Stimulation (TMS) System is a class II medical device that produces brief duration, pulsed magnetic fields. These rapidly alternating fields induce electrical currents within localized, targeted regions of the cortex which are associated with various physiological and functional brain changes. In 2007, O'Reardon et al., utilizing the NeuroStar device, published the results of an industry-sponsored, multisite, randomized, sham-stimulation controlled clinical trial in which 301 patients with major depression, who had previously failed to respond to at least one adequate antidepressant treatment trial, underwent either active or sham TMS over the left dorsolateral prefrontal cortex (DLPFC)...
2010: Journal of Visualized Experiments: JoVE
Timothy Derstine, Karl Lanocha, Carl Wahlstrom, Todd M Hutton
Another option for managing major depressive disorder (MDD) became available in October 2008 with the Food and Drug Administration's (FDA) market clearance of NeuroStar TMS (transcranial magnetic stimulation) Therapy System. A panel of psychiatrists who have been treating patients with NeuroStar TMS Therapy in their clinics assembled for a virtual roundtable discussion regarding their experiences. In this supplement, the panel addresses the following issues: the FDA-cleared indication for use of NeuroStar TMS Therapy; logistic and staffing considerations in the outpatient setting; selecting the right patient for TMS Therapy; talking with patients and family about TMS Therapy...
November 2010: Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists
Jared C Horvath, Jennifer M Perez, Lachlan Forrow, Felipe Fregni, Alvaro Pascual-Leone
Transcranial Magnetic Stimulation (TMS) is a non-invasive neurostimulatory and neuromodulatory technique increasingly used in clinical and research practices around the world. Historically, the ethical considerations guiding the therapeutic practice of TMS were largely concerned with aspects of subject safety in clinical trials. While safety remains of paramount importance, the recent US Food and Drug Administration approval of the Neuronetics NeuroStar TMS device for the treatment of specific medication-resistant depression has raised a number of additional ethical concerns, including marketing, off-label use and technician certification...
March 2011: Journal of Medical Ethics
C Schönfeldt-Lecuona, L Cárdenas-Morales, R W Freudenmann, T Kammer, U Herwig
Looking at novelties and advances in medicine in particular in the treatment of major depressive disorder no principally new antidepressant treatment strategy has been established in clinical routine in the last fifty years. However, regarding the considerable issue of treatment resistance in depression, new therapeutic strategies are urgently required. In this context, repetitive transcranial magnetic stimulation above the dorsolateral prefrontal cortex has been proposed as a potential new treatment option for depression; furthermore, in October 2008 a first rTMS-device (NeuroStar TMS Therapy System) was approved by the FDA for the treatment of treatment resistant major refractory depression in adults...
2010: Restorative Neurology and Neuroscience
(no author information available yet)
No abstract text is available yet for this article.
January 2010: OR Manager
(no author information available yet)
The FDA has cleared a new device for treatment of major depressive disorder (MDD) resistant to antidepressant medication. The NeuroStar TMS System (Neuronetics) produces pulsed magnetic fields that can induce electrical currents in the brain. Unlike electroconvulsive therapy (ECT), it does not require anesthesia or induction of seizures. Other similar devices are under development.
February 9, 2009: Medical Letter on Drugs and Therapeutics
Sornjarod Oonsiri, Chotika Jumpangern, Taweap Sanghangthum, Anchali Krisanachinda, Sivalee Suriyapee
OBJECTIVE: The purposes of the present study were to determine the dose to medical staff in interventional radiology at different locations on the body measured by thermoluminescent dosimeter (TLD) and to relate the medical staff dose to patient dose measured by the dose-area product (DAP) meter. MATERIAL AND METHOD: The present study covered 42 patients in three interventional radiology procedures with three x-ray machines. Thermoluminescent dosimeters were stuck at eight positions on the radiologist's skin during the procedure...
April 2007: Journal of the Medical Association of Thailand, Chotmaihet Thangphaet
Hank Grant, Donald Heirman, Glenn Kuriger, Murali Manohar Ravindran
Several clinical and laboratory studies have demonstrated electromagnetic interaction between implantable medical devices like pacemakers and cell phones being operated in close proximity. Those devices are largely now immune to phone interaction or procedures have been established to limit their interaction. The use of cell phones near people with implanted neural stimulators has not been studied. This research was initiated to investigate electromagnetic interaction between current cell phone technology and specific models of Cyberonics neural stimulators...
July 2004: Bioelectromagnetics
V Perilli, L Sollazzi, M Valenti, A M D'Alessandro, M Lo Monaco, G Pelosi
The successful management of 2 cases of rare myopathies, who underwent hemithyroidectomy, is here reported. Anaesthesia was induced with TPS and fentanyl, and maintained with isoflurane. Neuromuscular blockade was achieved by atracurium; neuromuscular monitoring by Neurostar-Medeleck was performed. This intraoperative monitoring allowed a quick recovery without complications.
July 1991: Minerva Anestesiologica
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"